Phase II study of short course CHOP-rituximab followed by 90-y ibritumomab tiuxetan as first-line treatment for follicular lymphoma: Extended follow-up and predictors of relapse. Background: There is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback